These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28722153)

  • 1. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.
    Kropeit D; Scheuenpflug J; Erb-Zohar K; Halabi A; Stobernack HP; Hulskotte EGJ; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Sep; 83(9):1944-1953. PubMed ID: 28345163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
    Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
    J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
    Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
    Asari K; Ishii M; Yoshitsugu H; Wakana A; Fancourt C; Yoon E; Furihata K; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Aug; 11(8):938-948. PubMed ID: 35238179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
    Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
    Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
    Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Hydroxypropyl β-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial.
    Erb-Zohar K; Kropeit D; Scheuenpflug J; Stobernack HP; Hulskotte E; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
    Clin Transl Sci; 2017 Nov; 10(6):487-495. PubMed ID: 28675594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
    Deleenheer B; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation.
    Suetsugu K; Shigematsu T; Nakamura T; Hirota T; Ieiri I
    Clin Pharmacokinet; 2024 Jul; 63(7):945-964. PubMed ID: 39012618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
    Pérez Marín M; Decosterd LA; Andre P; Buclin T; Mercier T; Murray K; Rizzi M; Meylan P; Jaton-Ogay K; Opota O; Gengler C; Perez MH; Natterer J; Asner SA
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):96-99. PubMed ID: 31183500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
    Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
    Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
    Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
    Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir: First Global Approval.
    Kim ES
    Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.